About Alligator Bioscience
Alligator Bioscience is a publicly listed company based in Lund (Sweden) founded in 2001. Alligator Bioscience is focused on tumor-directed cancer immunotherapy development. It operates on a HealthTech model. Alligator Bioscience has raised $10 million across 2 funding rounds from investors including Vinnova. Alligator Bioscience offers products and services including Mitazalimab, ATOR-4066, and ALG.APV-527. Its focus areas include Biotechnology and Cancer Immunotherapy. Its legal entity is Alligator Bioscience AB.
Company details
Alligator Bioscience is engaged in the development of antibody-based pharmaceuticals for cancer treatment. The company is specialized in tumor-directed immunotherapies, particularly agonistic mono- and bispecific antibodies. Solutions are developed within the biotechnology sector, targeting innovative approaches to combat metastatic cancers like pancreatic cancer. Research and development efforts are centered on a pipeline of candidates such as Mitazalimab, ATOR-4066, and ALG.APV-527, aimed at improving patient outcomes through advanced therapeutic technologies.
- Headquarters Lund, Sweden
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website alligatorbioscience.se/en
- Social LinkedIn X
- Legal Name Alligator Bioscience Ab
- Annual Revenue$55.81 K (USD)-99.11as on Dec 31, 2025
- Net Profit-$5.58 M (USD)78.05as on Dec 31, 2025
- EBITDA-$13.06 M (USD)33.13as on Dec 31, 2025
- Total Equity Funding$10M (USD)
in 2 rounds
- Latest Funding Round$55.05K (USD), Grant
Oct 2018
- Investors
Products & Services of Alligator Bioscience
Alligator Bioscience offers a comprehensive portfolio of products and services, including Mitazalimab, ATOR-4066, and ALG.APV-527.
Developed as a tumor-directed immunotherapy for cancer treatment.
Designed as an antibody-based solution for cancer therapy.
Created for targeted cancer treatment using antibody technology.
Funding Insights of Alligator Bioscience
Alligator Bioscience has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $55.05 thousand completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 2
- Last Round Grant — $55,050
- First Round $10M
(Oct 2015)
- Investors Count 1
All 2 funding rounds of Alligator Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $55,050 | Grant | – | – | |
| Oct 2015 | $10M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Alligator Bioscience
Alligator Bioscience has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Vinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to Swedish companies across sectors. | 2001 | vinnova.se | Stockholm, Sweden |
Investor details for Alligator Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alligator Bioscience
19 people are tracked at Alligator Bioscience (6 in leadership, 6 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Yago Pico de Coaña | Medical Science Director | Leadership |
Karin Hägerbrand | Director, Discovery Biology | Leadership |
Søren Bregenholt | CEO | Leadership |
Sumeet Ambarkhane | CMO | Leadership |
Johan Gileus | Chief Financial Officer | Leadership |
Ulla Holm Hansen | VP Clinical Operations | Leadership |
Eva Sjökvist Saers | Board Member | Board & advisors |
Denise Goode | Board Member | Board & advisors |
Staffan Encrantz | Board Member | Board & advisors |
Veronica Wallin | Board Member | Board & advisors |
Hans-Peter Ostler | Vice Chairman | Board & advisors |
Graham Dixon | Board Member | Board & advisors |
Ida Uddbäck | Senior Scientist And Team Leader | Team |
David Gómez Jiménez | Translational Scientist | Team |
Matthías Thórólfsson | Principal Scientist | Team |
Peter Ellmark | CSO | Team |
Ida Åberg | Research Engineer | Team |
Hampus Andersson | Industrial PHD Student | Team |
Jenny Björsne | Group Accountant | Team |
Complete people profiles for Alligator Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alligator Bioscience
Alligator Bioscience is a publicly listed company on the OMXSTO with ticker symbol ATORX in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Nov 2016
- Listed onNASDAQ OMX: ATORX
- Listed entityAlligator Bioscience AB
- Exchange sectorHealth technology
- ISINSE0024173637
- Share price0.01 SEK (-4.08% on the day) · 2026-10-14
- Market capitalisation51,075,402.00 SEK
- EPS (diluted, trailing year)-0.55 SEK
- Volume (last session)47,101,584
Financials of Alligator Bioscience
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 514,000 SEK | -51.4M SEK | -120.3M SEK |
| 2024 | 57.8M SEK | -233.9M SEK | -179.9M SEK |
| 2023 | 58.1M SEK | -248.6M SEK | -242.3M SEK |
| 2022 | 35.7M SEK | -193.4M SEK | -182.5M SEK |
| 2021 | 12.9M SEK | -141.7M SEK | -132.6M SEK |
Detailed financial statements for Alligator Bioscience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Alligator Bioscience
4 dated milestones of Alligator Bioscience across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Alligator Bioscience is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $55K.
Web traffic of Alligator Bioscience
The website of Alligator Bioscience (alligatorbioscience.se) receives about 9.9K visits a month and ranks #1,706,633 among all websites worldwide, #2,308 in Biotechnology and Pharmaceuticals.
- Monthly visits9.9K
▼ 30.9% vs previous month
- Unique visitors6.6K
per month
- Global rank#1,706,633
among all websites
- Category rank#2,308
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit1.7
- Average visit3 min 10 sec
- DevicesDesktop 11% · Mobile 89%
Websites whose visitors overlap most with Alligator Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| altorbioscience.com | 100% | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alligator Bioscience
Complete news archive for Alligator Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alligator Bioscience
Alligator Bioscience was founded in 2001 and raised its 1st funding round 14 years after it was founded.
Alligator Bioscience is headquartered in Lund, Sweden.
Alligator Bioscience is a funded company, having raised a total of $10M across 2 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Oct 2015.
Annual revenue of Alligator Bioscience is $55.81K as on Dec 31, 2025.
Alligator Bioscience is engaged in the development of antibody-based pharmaceuticals for cancer treatment. The company is specialized in tumor-directed immunotherapies, particularly agonistic mono- and bispecific antibodies. Solutions are developed within the biotechnology sector, targeting innovative approaches to combat metastatic cancers like pancreatic cancer. Research and development efforts are centered on a pipeline of candidates such as Mitazalimab, ATOR-4066, and ALG.APV-527, aimed at improving patient outcomes through advanced therapeutic technologies.
Alligator Bioscience offers Mitazalimab, ATOR-4066, and ALG.APV-527.
Yes, Alligator Bioscience is publicly traded on OMXSTO under the ticker symbol ATORX.
Alligator Bioscience has 1 investor. Key investors include Vinnova.
Alligator Bioscience operates through Alligator Bioscience Ab.